Its funny Savov is claiming not to have done business with ENZC when he was issued shares in 2018. There is proof in the paper trail, and official documents. When the plan to merge im 2017 fell through in 2018, he was issued shares instead. I can see why he would be bitter, lol.
Its all in the filings.
Item VI. The nature of the issuer’s business.
On July 21, 2017 the Company submitted a Corporate Action requesting a name and symbol change, as a required by the merger agreement, to change the name of the Company from Eco-Petroleum Solutions, Inc. to Immunotech
Laboratories, Inc. to indicate the Company’s entrance into the Drug Development Industry for Immunotherapies. The Company has received comments and responded and expects the process to be completed shortly. The request
was subsequently withdrawn, and the merger agreement terminated.
On October 25, 2017 the Company’s subsidiary Immunotech Laboratories, Inc. submitted a request to for the retirement of the Immunotech Laboratories, Inc. symbol IMMB from the OTC Market. The request was subsequently denied, and a deficiency letter issued resulting in the termination of the merger agreement.
On January 15, 2018 the merger agreement with Immunotech Laboratories, Inc. was terminated except for Section 1.03(d)(i) which relates to the appointment of Harry Zhabilov as Chairman and CEO of ECPO which remains in effect.
On January 30, 2018 a new Corporate action was filed by the Company to change its name from Eco-Petroleum Solutions, Inc. to Enzolytics, Inc. to better represent the new business strategy. The Corporate action was approved on
March 22nd and the ticker symbol was changed from ECPO to ENZC. The amendment to the Articles of Incorporation in the state of Delaware were filed on January 17, of 2018 changing the name to Enzolytics, Inc.
On March 26, 2018 an asset purchase agreement was entered with Immunotech Laboratories, Inc whereby the Exclusive License Agreement for the Patented Immunotherapy Treatment for the care of HIV/Aids and Hepatitis C patients, the Forty Nine Percent ownership in Immunotech Laboratories BG, all equipment and licensing of intellectual property associated with the Patented treatment in exchange for a secured note receivable, common stock
of Enzolytics, Inc. issued to Immunotech Laboratories, Inc. and assumption of certain debt from Immunotech by
Enzolytics, Inc.
On March 23,2018 the Company issued 78,400,000 common shares to Dimita Slachev Savov for services rendered in implementing the business strategy in Bulgaria.
Market Data 
Markets 
AI
